Drugs / nolatrexed
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00012324 | Sep 2000 → Nov 2005 | liver cancer | Eximias Pharmaceutical | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nolatrexed | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00012324 ↗ |
| Action | Inhibit | “Thymidylate synthase antagonist” CHEMBL320775 ↗ |
| Modality | Small molecule | — CHEMBL320775 ↗ |
| Route | Intravenous | “Patients receive nolatrexed dihydrochloride IV continuously on days 1-5.” NCT00012324 ↗ |
| Target | TYMS | “Thymidylate synthase antagonist” CHEMBL320775 ↗ |